Psychiatr. praxi 2017; 18(3): 114-119 | DOI: 10.36290/psy.2017.021

Novel trends in treatment of obsessive-compulsive disorder

MUDr. Pavla Stopková, Ph.D.
Národní ústav duševního zdraví, Klecany
3. lékařská fakulta UK Praha

The aim of this paper is to summarize current treatments of obsessive-compulsive disorder (OCD) and to describe novel therapeuticalstrategies in the fields of pharmacotherapy, psychotherapy, stimulation, and neurosurgery. The use of SSRI antidepressantshas a well documented efficacy and growing evidence supports augmentation of SSRI with atypical antipsychotics. A promisingbut not yet established field is represented by glutaminergic modulators. Cognitive behavioral psychotherapy (CBT) is the mosteffective psychotherapy and evidence supports also the use of remote CBT – computer-based and on-line CBT. AcceptanceCommitment Therapy introduces a promising approach in the field of psychotherapy. More attention is focused on the role ofthe family in the treatment of OCD symptoms. Other treatment modalities are represented by stimulation methods – rTMS andtDCS. Neurosurgery with ablative procedures or deep brain stimulation provides an alternative for treatment refractory patients.

Keywords: obsessive-compulsive disorder, SSRI, augmentation, glutamate, cognitive-behavioral therapy, stimulation, neurosurgery

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stopková P. Novel trends in treatment of obsessive-compulsive disorder. Psychiatr. praxi. 2017;18(3):114-119. doi: 10.36290/psy.2017.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pallanti S, Hollander E, Bienstock C, et al. International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002; 5(2): 181-191. Go to original source... Go to PubMed...
    2. Goodman WK, Price LH, Rasmussen SA, Mazure C, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989; 46(11): 1006-1011. Go to original source... Go to PubMed...
    3. Farris SG, McLean CP, Van Meter PE, et al. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013; 74(7): 685-690. Go to original source... Go to PubMed...
    4. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010; 15(8): 850-855. Go to original source... Go to PubMed...
    5. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012; 15(8): 1173-1191. Go to original source... Go to PubMed...
    6. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder.Int Clin Psychopharmacol. 2001; 16(1): 33-38. Go to original source... Go to PubMed...
    7. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs. 2011; 25(7): 585-596. Review. Go to original source... Go to PubMed...
    8. Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail. Australas Psychiatry. 2015; 23(4): 350-353. Review. Go to original source... Go to PubMed...
    9. Andrade C. Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks. J Clin Psychiatry. 2013; 74(12): e1128-1133. Go to original source... Go to PubMed...
    10. Metin O, Yazici K, Tot S, Yazici AE. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003; 18(6): 463-467. Go to original source... Go to PubMed...
    11. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.Int J Neuropsychopharmacol. 2015; 18(9). Go to original source... Go to PubMed...
    12. Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013; 70(11): 1190-1199. Go to original source... Go to PubMed...
    13. Pittenger C. Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry. 2015; 2(3): 271-283. Go to original source... Go to PubMed...
    14. Bruno A, Mic? U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012; 26(11): 1456-1462. Go to original source... Go to PubMed...
    15. Whittal ML, Robichaud M, Thordarson DS, McLean PD. Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. J Consult Clin Psychol. 2008; 76(6): 1003-1014. Go to original source... Go to PubMed...
    16. Öst LG, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014. Clin Psychol Rev. 2015; 40: 156-69. Review. Go to original source... Go to PubMed...
    17. Vyskocilova J, Prasko J, Sipek J. Cognitive behavioral therapy in pharmacoresistant obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2016; 12: 625-639. Go to original source...
    18. Wootton BM. Remote cognitive-behavior therapy for obsessive-compulsive symptoms: A meta-analysis. Clin Psychol Rev. 2016; 43: 103-113. Review. Go to original source... Go to PubMed...
    19. Crino RD. Psychological treatment of obsessive compulsive disorder: an update. Australas Psychiatry. 2015; 23(4): 347-349. Review. Go to original source... Go to PubMed...
    20. Saba G, Moukheiber A, Pelissolo A. Transcranial cortical stimulation in the treatment of obsessive-compulsive disorders: efficacy studies. Curr Psychiatry Rep. 2015; 17(5): 36. Go to original source... Go to PubMed...
    21. Palm U, Leitner B, Kirsch B, et al. Prefrontal tDCS and sertraline in obsessive compulsive disorder: a case report and review of the literature. Neurocase. 2017; 23(2): 73-177. Go to original source... Go to PubMed...
    22. Brown LT, Mikell CB, Youngerman BE, et al. Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies. J Neurosurg. 2016; 124(1): 77-89. Go to original source... Go to PubMed...
    23. Alonso P, Cuadras D, Gabriëls L, et al. Deep Brain Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One. 2015; 10(7). Go to original source...
    24. Pepper J, Hariz M, Zrinzo L. Deep brain stimulation versus anterior capsulotomy for obsessive-compulsive disorder: a review of the literature. J Neurosurg. 2015; 122(5): 1028-1037. Go to original source... Go to PubMed...
    25. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017; 317(13): 1358-1367. Review. Go to original source... Go to PubMed...
    26. Katzman MA, Bleau P, Blier P, et al. Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014; 14 Suppl 1: S1. Review. Go to original source... Go to PubMed...
    27. Seibell PJ, Hollander E. Management of obsessive-compulsive disorder. F1000Prime Rep. 2014; 6: 68. Go to original source... Go to PubMed...
    28. Costa DLC, Diniz JB, Requena G, et al. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. J Clin Psychiatry. 2017; 78(7). Go to original source... Go to PubMed...
    29. Emamzadehfard S, Kamaloo A, Paydary K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016; 70(8): 332-341. Go to original source... Go to PubMed...
    30. Esalatmanesh S, Abrishami Z, Zeinoddini A, et al. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry Clin Neurosci. 2016; 70(11): 517-526. Go to original source... Go to PubMed...
    31. van Oppen P, van Balkom AJ, de Haan E, van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005; 66(11): 1415-1422. Go to original source... Go to PubMed...
    32. Twohig MP, Hayes SC, Plumb JC, et al. A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol. 2010; 78(5): 705-716. Go to original source... Go to PubMed...
    33. Albert U, Bogetto F, Maina G, et al. Family accommodation in obsessive-compulsive disorder: Relation to symptom dimensions, clinical and family characteristics. Psychiatry Res. 2010; 179(2): 204-211. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.